SPIA
NVCT icon

Steward Partners Investment Advisory’s Nuvectis Pharma NVCT Stock Holding History

Steward Partners Investment Advisory’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$773 Hold
100
– – ﹤0.01% 4223
2025
Q4 		$755 Hold
100
– – ﹤0.01% 4118
2025
Q3 		$602 Hold
100
– – ﹤0.01% 4107
2025
Q2 		$747 Hold
100
– – ﹤0.01% 3915
2025
Q1 		$977 Hold
100
– – ﹤0.01% 3776
2024
Q4 		$541 Hold
100
– – ﹤0.01% 3839
2024
Q3 		$629 Hold
100
– – ﹤0.01% 3571
2024
Q2 		$633 Buy
+100
New +$680 ﹤0.01% 3447

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Steward Partners Investment Advisory's NVCT Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Nuvectis Pharma (NVCT) position steady in Q1 2026 at 100 shares worth $773. The position accounts for ﹤0.01% of the portfolio, ranked #4223.

Steward Partners Investment Advisory first reported a position in NVCT in Q2 2024 and has held it in 8 quarters since. The position peaked at $977 in Q1 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Steward Partners Investment Advisory held 100 shares of Nuvectis Pharma worth $773 as of Q1 2026.
  • Steward Partners Investment Advisory left its Nuvectis Pharma share count unchanged in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4223 holding.
  • Steward Partners Investment Advisory first reported a position in Nuvectis Pharma in Q2 2024 and has held it in 8 quarters since.
  • Steward Partners Investment Advisory's Nuvectis Pharma position peaked at $977 in Q1 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.